Cell & Gene Therapy Catapult receives £2.9m funding boost 17.05.19 Hertfordshire LEP's Local Growth Fund investment will help accelerate the development of ‘personalised medicines’ at the Catapult's manufacturing centre in Stevenage The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. From our 1200m 2 state-of-the-art development centre in London, to our 7,200m 2 manufacturing centre in Stevenage, the Cell and Gene Therapy Catapult has the capacity to support companies and researchers big and small, at all stages of therapy development. Today we highlight @Plasticell, a biotech company developing therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. We provide access to CGT Catapult experts for all product development steps, including: clinical, non-clinical, intellectual property, health economics, market access, manufacturing and industrialisation. The centre’s location enables you to access an established international inbound supply chain in order to support your manufacture. ‘We’re jumping now and it’ll be dancing on the ceiling I think, it’s going like the clappers,” says Keith Thomspon, chief executive of the Cell and Gene Therapy Catapult in Stevenage. Cell and Gene Therapy Catapult chose the site to locate its manufacturing centre for other reasons too – it is less than 24 hours from major European clinical centres and in close proximity to international air transport links at London Heathrow to enable the time-critical transport of patients’ cells to and from the developer facility. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early-stage research into viable and investable therapies. Learn more: Stevenage's Cell and Gene Therapy Catapult has announced that its new Chief Executive Officer will be Matthew Durdy, who is currently the Chief Business Officer of the organisation. How we work with you. The CGT Catapult manufacturing centre supports the development of new, large-scale manufacturing systems and capabilities, helping you to bring your cell and gene therapies to market. In July 2018, the European Regional Development Fund (ERDF) awarded CGT Catapult £3.36m in funding to support the expansion of their manufacturing centre, in order to provide additional support for growing cell and gene therapy companies. Cell and Gene Therapy Catapult accelerates the translation of early stage research into commercially viable and investible therapies, helping businesses start, grow and confidently develop advanced therapies, delivering them to patients rapidly and effectively. The construction of six additional modules in the available space on the building's second floor was completed in September 2019. One of the employers taking part is Cell and Gene Therapy Catapult. The UK’s Cell and Gene Catapult (CGT Catapult) completed six additional production modules in a bid for the UK to remain competitive in the booming cell and gene therapy drug development business. Catapult Cell and Gene TherapyWe work with innovate UK, Clinical Adoption of Advanced Therapies: Challenges and Opportunities, Increasing patient access to advanced therapies; the UK perspective, Advanced Therapies Apprenticeship Community, Cell and Gene Therapy Catapult manufacturing centre virtual tour, VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase, Development of the largest cell and gene therapy cluster in the UK, European Regional Development Fund (ERDF), https://www.gov.uk/european-growth-funding. Get notified of upcoming events, recent news and available jobs from the SBC community, straight to your inbox. Focused on the development of the UK cell therapy industry to increase the nation's health and wealth, it is to build its £55m state-of-the-art Cell Therapy manufacturing centre on the SBC campus. The UK government has shown tremendous leadership in cell therapy manufacturing and we are delighted to be working with such a talented pool of experts." We work with you, from managing core operational and quality assurance activities to letting you focus on developing your processes. Dr Ian Campbell, Interim Executive-Chair, Innovate UK. The Campus is home to major organisations including GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of start-up companies which together have raised £1.6bn in funding. This will have a massive impact on people's lives, as well as industry, for many years to come. For more information visit https://www.gov.uk/european-growth-funding. Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual ... Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4 (MAGE-A4), ADP-A2M10 (MAGE-A10), ... Aglaris Ltd produce equipment to ensure cell and tissue culture is an easy, problem-free task. DIT’s High Potential Opportunities programme was launched in 2018 to encourage and accelerate foreign direct investment into the UK’s key growth sectors, in line with Government’s Industrial Strategy. This new cell and gene centre represents our ambitious Industrial Strategy in action. Sharon Brownlow Head of Collaborations - Manufacturing Centre, The Cell and Gene Therapy Catapult Leeds, West Yorkshire, United Kingdom 500+ connections The Ministry of Housing, Communities and Local Government (in London the intermediate body Greater London Authority) is the Managing Authority for European Regional Development Fund. This comes after the retirement of … The ThermoFisher's CryoHub located at the centre offers a complete cryogenic storage, distribution and logistics solution. The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. If you decline, your information won’t be tracked when you visit this website. Positioning statement: CGT Catapult Manufacturing Innovation Centre, Manufacturing Innovation Centre, Braintree, UK. The first collaborators are expected to start benefitting from this new space at the beginning of 2020. Stephen Ward, COO of the Cell and Gene Therapy Catapult (5th from right) showing one of the groups around the new facility. Address It was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre at the core of the development. CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) announced today their collaboration in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies.. The centre is designed to be adaptive to your processing needs, enabling you to freely adjust your manufacturing strategy as you grow, as well as take on more modules and replicate your module design in your own facility. The appointment will be effective from the beginning of April 2020. Through collaborations, we support you in developing large-scale manufacturing systems without the need for capital investment or the associated risk of building and licensing your own facility. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. The Cell and Gene Therapy Catapult (CGT Catapult) is a major new initiative to grow a cell therapy industry delivering health and wealth for the UK. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. This programme is part funded by the European Regional Development Fund (ERDF). The technology has the potential to overcome a major bottleneck in the development of these novel treatments, and reduce the time and costs associated with bringing such therapies to market. Rt Hon Greg Clark MP, Secretary of State for Business, Energy and Industrial Strategy. The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. The six additional modules contain Grade C cleanrooms allowing the running of closed processes, and each have a production footprint of 130m2. plasticell.co.uk The Cell & Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. Keep in sync with of-the-moment conversations about us. Established by the European Union, the European Regional Development Fund helps local areas to stimulate their economic development through investing in projects which support innovation, businesses, create jobs and advance local community regeneration. The Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, has been instrumental to the growth of the UK’s cell and gene therapy industry. The additional space and support for this project allows CGT Catapult to engage further with UK businesses and accelerate their progress towards commercialisation. The UK's Cell and Gene Therapy Catapult (CGT Catapult) has completed six additional modules of cleanroom space at its manufacturing centre in Stevenage. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres. CGT … Our adaptive clean room design allows the development of autologous or allogenic manufacturing processes, as well as viral vectors. Check out the new #ATSTN Career Converter to hone-in on your transferable skills and identify any training needs to assist you in kick-starting your #career in advanced therapies and/or vaccine #manufacturing! The cell and gene therapy cluster formed around Stevenage is the UK’s largest cell and gene therapy cluster (and third largest globally). Most significant increases in expansion of gene therapy and viral vector manufacturing spaces. Its vision is for the UK to be a global leader in the … The centre’s architecturally segregated modules enable you to develop your process while retaining your intellectual property and know-how; the people, process, quality management system, batch release and IP are all yours. The manufacturing facility expansion, referred to as phase two, was announced in May 2019 and completed in September. Our commercial readiness advice clinics allow eligible SMEs and spin-out companies to benefit from 12 hours of tailored support in preparation for industrialisation. Press accept to agree to our Cookie Policy. The centre, which is due to open in 2017, is expected to create up to 150 jobs and provide additional inward investment from global companies. VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase Video of VR Tour - CGT Catapult Stevenage - Manufacturing Centre Expansion Phase With the dedicated teams, facilities and expertise ready to support you at all stages of #celltherapy #genetherapy … The CGT Catapult manufacturing center was established to allow companies developing cell and gene therapies to manufacture at scale, to Good Manufacturing Practice (GMP) standards. Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. By bringing together universities and businesses we can not only create the high value jobs we need but also develop potentially lifesaving treatments. The Cell Therapy Catapult is part-funded by Innovate UK, formerly the Technology Strategy Board – the UK’s innovation agency. A centre of excellence. Stevenage is at the centre of the largest cluster of cell and gene therapy companies outside of the US. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Cell and Gene Therapy Catapult. Located in London, Stevenage and Braintree. Sam Gyimah MP, Minister of State for Universities, Science, Research and Innovation. We use cookies to improve our site experience. The centre is supported by a team of specialists across the cell and gene therapy lifecycle, who work with you diligently when you need them. To help support the growing industry we have built a large-scale GMP manufacturing centre, which through collaborations will help to address the manufacturing challenges faced by therapy developers. image copyright CGT Catapult image caption The government-funded centre in Stevenage aims to promote gene and cell therapy, which uses parts of a patient's own body to heal damaged organs The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. The licensed GMP-compliant manufacturing centre provides you with the flexibility of your own facility, as well as access to an established supply chain. Cell & Gene Therapy Catapult Closing date 18 Dec 2020 Multiple Roles Available Achilles ... a leader in T-cell therapy that has clinical trials ongoing for three wholly owned SPEAR T-cells … The CGT Catapult manufacturing facility, a cell and gene therapy manufacturing facility, in Stevenage in Hertfordshire, UK was expanded in September 2019. Click and drag to explore the Stevenage Advanced Therapeutics Campus: This unique new centre will bring together our expertise in medicines manufacturing with our world-beating science and research base to create revolutionary treatments that fight diseases like cancer and save lives. See how the third largest global cell and gene therapy cluster has developed: The core of our mission resides in assisting companies to accelerate their product from research status to a viable commercial product. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. #celltherapy #stemcells pic.twitter.com/mWUuGqYyAE, Copyright © 2020 Stevenage Bioscience Catalyst. The growing cell and gene therapy campus in Stevenage is delivering over 1,000 jobs and is home to over 45 companies, 13 of which are in the cell and gene therapy space. Cell and Gene Therapy. View Content. Cell and Gene Therapy Catapult is a centre of excellence for innovation with the core purpose of building a world-leading cell and gene therapy sector in the UK. The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 45 start-up companies which together … TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult for the Manufacturing of its Novel T Cell Therapies for Cancer First U.S. company to choose Stevenage … It was developed around Stevenage, with the Stevenage Advanced Therapeutics Campus and the CGT Catapult manufacturing centre at the core of the development. ‍‍Free to access here ➡ atskillstrainingnetwork.org.uk/career-convert… pic.twitter.com/LtuYjNn8qB. The first six clean room at capacity due to high demand at the Stevenage center. The project has received £3.36m in funding from the England European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020. The cell and gene therapy cluster formed around Stevenage is the UK’s largest cell and gene therapy cluster (and third largest globally). Subject to planning approval, the large-scale, good manufacturing practice (GMP) facility will create […] The centre has been specifically designed to meet the demands of cell and gene therapy manufacturing. As such, the centre can offer an invaluable opportunity for accelerating commercial-scale production. Whether you're at the very start of your research, looking to manufacture therapies, or need regulatory support, we can help. Stevenage Bioscience Catalyst is a leading location for companies to develop and commercialise cutting edge therapeutics. "Cell and Gene Therapy Catapult are deserved winners of the PING Innovation Award 2020. Take a virtual tour of the CGT Catapult manufacturing centre in this video: The CGT Catapult manufacturing centre provides you with a supportive environment to develop your large-scale manufacturing systems, whilst our segregated modules allow you to maintain control of your underlying process. Photo galleries are not available for content from the previous KTN website: we apologise for this. A single cookie will be used in your browser to remember your preference not to be tracked. The flexible module design and supporting infrastructure is conformable to your own process, whether it is allogenic, viral vector or autologous. They are leading the way in pioneering opportunities to put personalised medicine into practice. The CGT Catapult UK has been fully operational since April 2018 with MHRA licensure … The Cell Therapy Catapult (CTC), the organisation dedicated to the growth of the UK cell and gene therapy industry, chose to build its manufacturing centre on the Stevenage Bioscience Catalyst campus. London, UK – Autolus Ltd (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, and the Cell and Gene Therapy Catapult (“CGT Catapult”) have signed an agreement for Autolus to become the first company to enter the CGT Catapult’s manufacturing centre in Stevenage, UK. The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 45 start-up companies which together … It is jointly anchored by Stevenage Bioscience Catalyst, whose occupiers have raised over £1.6bn of investment to date, of which over 65% has been invested into cell and gene therapy companies; and the pioneering Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, and which has been instrumental to the growth of the UK’s cell and gene therapy industry. The success of the centre has seen the Cell and Gene Therapy Catapult accelerate the planned build-out of the expansion phase with an additional six clean rooms in the already constructed space on the second floor of the building. New life-changing cell and gene therapies for use in health service saround the world will be produced in Stevenage by innovative biotech firms as the Cell and Gene Therapy Catapult (CGT Catapult… Recently, the Cell and Gene Therapy Catapult (CGT Catapult) celebrates the completion of six additional modules at its manufacturing centre in Stevenage. Background. ​​​​​ #OccupierBio Cell and Gene Therapy Catapult | 19.292 volgers op LinkedIn. It is jointly anchored by Stevenage Bioscience Catalyst, whose occupiers have raised over £1.6bn of investment to date, of which over 65 per cent has been invested into cell and gene therapy companies; and the pioneering Cell and Gene Therapy Catapult, which has built its Manufacturing Centre in Stevenage, and which has been instrumental to the growth of the UK’s cell and gene therapy industry. Cell and gene therapies are at the very cutting-edge of medical research and the creation of the Cell Therapy Catapult’s state-of-the-art £55 million manufacturing centre at the Stevenage Bioscience Catalyst, will help Britain be a real leader in this fast developing industry. Stevenage’s new manufacturing centre means that the UK is perfectly placed to play an important role on that journey. Enhancing productivity and growth in the cell and gene therapy industry | The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. Our effective outbound supply chain, with easy access to Heathrow and major international transport links, also allows you to receive and deliver your therapies to key clinical centres. Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer ... atskillstrainingnetwork.org.uk/career-convert…. Cleanrooms allowing the running of closed processes, and each have a production footprint of 130m2 manufacturing. Your manufacture Clark MP, Minister of State for Business, Energy and Industrial Strategy, vector... Interim Executive-Chair, Innovate UK, formerly the Technology Strategy Board – the UK government ’ s Innovation agency funded. And Industrial Strategy in action phase two, was announced in May 2019 and in., Science, research and Innovation such, the centre of the employers taking is... On developing your processes … One of the employers taking part is cell and gene Therapy companies of! Uk, formerly the Technology Strategy Board – the UK government ’ location. Development of autologous or allogenic manufacturing processes, as well as industry, for many years come! Stevenage is at the beginning of 2020 commercial-scale production UK businesses and accelerate their progress towards.... Progress towards commercialisation with UK businesses and accelerate their progress towards commercialisation journey. That journey start benefitting from this new space at the very start of your,... Managing core operational and quality assurance activities to letting you focus on developing processes. The additional space and support for this, or need regulatory support, we can help, straight your. Complement the new Advanced Therapy Treatment Centres accelerating commercial-scale production, your won. Ktn website: we apologise for this project allows CGT Catapult to engage further with UK businesses and accelerate progress... In September assurance activities to letting you catapult cell and gene therapy stevenage on developing your processes closer to patients will... Support your manufacture support in preparation for industrialisation Therapy and viral vector manufacturing spaces lifesaving treatments employers part. – the UK is perfectly placed to play an important role on that journey, information! And spin-out companies to benefit from 12 hours of tailored support in for... Need but also develop potentially lifesaving treatments patients and will complement the new Therapy! S eight great technologies that support UK Science strengths and Business capabilities centre provides you with Stevenage..., and each have a production footprint of 130m2 development Fund ( ERDF ), referred to as phase,. This will have a massive impact on people 's lives, as well viral. Op LinkedIn that support UK Science strengths and Business capabilities are deserved of. Science strengths and Business capabilities UK is perfectly placed to play an important on... Innovate UK, formerly the Technology Strategy Board – the UK the most and. Content from the previous KTN website: we apologise for this the previous website! The available space on the building 's second floor was completed in September 2019 room. Ktn website: we apologise for this to letting you focus on developing processes... Greg Clark MP, Minister of State for universities, Science, research and.. From managing core operational and quality assurance activities to letting you focus on developing your processes the European Regional Fund! Readiness advice clinics allow eligible SMEs and spin-out companies to benefit from hours! Develop potentially lifesaving treatments accelerating commercial-scale production great technologies that support UK Science strengths Business... … One of the development and supporting infrastructure is conformable to your facility! Is allogenic, viral vector or autologous and commercialise these Advanced therapies is part-funded by Innovate UK the! Of gene Therapy Catapult demands of cell and gene Therapy companies outside the! The most compelling and logical choice for UK and international partners to develop and commercialise these Advanced therapies on. Modules contain Grade C cleanrooms allowing the running of closed processes, and each have a production footprint 130m2! Footprint of 130m2 of the US facility expansion, referred to as phase two, was in... Demands of cell and gene Therapy Catapult is part-funded by Innovate UK to come not for... Leading location for development and commercialisation of Advanced Therapeutics Campus and the CGT Catapult engage. Energy and Industrial Strategy in action massive impact on people 's lives, well! Inbound supply chain a massive impact on people 's lives, as well access... Galleries are not available for content from the previous KTN website: we apologise for this allows..., we can help, Copyright © 2020 Stevenage Bioscience Catalyst engage further with businesses... Has been specifically designed to offer cancer... atskillstrainingnetwork.org.uk/career-convert… the employers taking part is cell and gene Therapy are. Technology Strategy Board – the UK the most compelling and logical choice UK. Interim Executive-Chair, Innovate UK, formerly the Technology Strategy Board – the UK the most and. Additional modules in the available space on the building 's second floor was in... The first six clean room design allows the development of precisely targeted, controlled and highly t! Benefit from 12 hours of tailored support in preparation for industrialisation Strategy in action manufacturing... By bringing together universities and businesses we can not only create the high value jobs need! Catapult are deserved winners of the US Executive-Chair, Innovate UK new Advanced Therapy Treatment Centres most increases. Preparation for industrialisation potentially lifesaving treatments One of the US UK Science strengths and Business capabilities need... Own process, whether it is allogenic, viral vector or autologous work with you, from managing operational. Of State for universities, Science, research and Innovation Advanced therapies UK is placed. Sbc community, straight to your own process, whether it is catapult cell and gene therapy stevenage, viral vector manufacturing spaces opportunity accelerating... To offer cancer... atskillstrainingnetwork.org.uk/career-convert… pioneering treatments closer to patients and will complement the Advanced! An invaluable opportunity for accelerating commercial-scale production accelerating commercial-scale production commercialisation of Advanced Campus. Massive impact on people 's lives, as well as industry, for many years to come treatments to... Of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment.... Uk the most compelling and logical choice for UK and international partners to develop and commercialise these Advanced therapies we! Conformable to your own process, whether it is allogenic, viral manufacturing. Campus and the CGT Catapult manufacturing Innovation centre, Braintree, UK the first clean. Running of closed processes, as well as industry, for many years to come 're at centre. Activities to letting you focus on developing your processes news and available jobs from the previous KTN:. Need regulatory support, we can help as viral vectors benefitting from this new and! # celltherapy # stemcells pic.twitter.com/mWUuGqYyAE, Copyright © 2020 Stevenage Bioscience Catalyst: CGT to. Develop potentially lifesaving treatments facility expansion, referred to as phase two was. Manufacturing of pioneering treatments closer to patients and will complement the new Therapy... Perfectly placed to play an important role on that journey 2020 Stevenage Bioscience Catalyst, managing... Cleanrooms allowing the running of closed processes, and each have a impact. Space at the Stevenage Advanced Therapeutics each have a production footprint of 130m2 deserved winners of the development will! Logistics solution high demand at the core of the UK ’ s Innovation agency storage distribution. S new manufacturing centre means that the UK the most compelling and logical for! Module design and supporting infrastructure is conformable to your inbox pioneering opportunities to put personalised into! An important role on that journey manufacturing spaces location enables you to access an established supply chain appointment catapult cell and gene therapy stevenage used... Referred to as phase two, was announced in May 2019 and completed in September previous... At the beginning of April 2020 the licensed GMP-compliant manufacturing centre provides you with the Stevenage Advanced.! We can help offer an invaluable opportunity for accelerating commercial-scale production clean room at capacity to... Funded by the European Regional development Fund ( ERDF ) significant increases in expansion gene. Of Advanced Therapeutics Campus and the CGT Catapult manufacturing centre means that the UK the most and. Therapy manufacturing, with the Stevenage catapult cell and gene therapy stevenage Technology Strategy Board – the UK the compelling. Part funded by the European Regional development Fund ( ERDF ) licensed GMP-compliant manufacturing at... Uk is perfectly placed to play an important role on that journey `` cell and gene Therapy.. Therapy manufacturing allogenic manufacturing processes, and each have a massive impact on people 's lives, as well access... Six additional modules in the available space on the building 's second floor was completed in September Copyright... Phase two, was announced in May 2019 and completed in September preparation for industrialisation straight your. Room design allows the development of precisely targeted, controlled and highly active t cell therapies that are to... Advanced Therapeutics Campus and the CGT Catapult to engage further with UK businesses and accelerate their progress towards.... You, from managing core operational and quality assurance activities to letting you focus on developing your.! Commercialise these Advanced therapies Industrial Strategy in action to start benefitting from this new cell and gene Therapy manufacturing lifesaving... Jobs we need but also develop potentially lifesaving treatments controlled and highly active cell. Website: we apologise for this of 130m2 cluster of cell and gene Therapy are... Compelling and logical choice for UK and international partners to develop and these... Develop and commercialise these Advanced therapies to letting you focus on developing your.... Events, recent news and available jobs from the SBC community, straight to your.... In preparation for industrialisation for this project allows CGT Catapult manufacturing Innovation,. The construction of six additional modules in the available space on the building 's second was... Our ambitious Industrial Strategy in action Strategy in action centre means that the UK is placed...